1. A Bayesian approach to probabilistic sensitivity analysis in structured benefit‐risk assessment. Issue 1 (28th January 2015) Authors: Waddingham, Ed; Mt‐Isa, Shahrul; Nixon, Richard; Ashby, Deborah Journal: Biometrical journal Issue: Volume 58:Issue 1(2016:Jan.) Page Start: 28 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A case study using the PrOACT‐URL and BRAT frameworks for structured benefit risk assessment. Issue 1 (26th January 2015) Authors: Nixon, Richard; Dierig, Christoph; Mt‐Isa, Shahrul; Stöckert, Isabelle; Tong, Thaison; Kuhls, Silvia; Hodgson, Gemma; Pears, John; Waddingham, Ed; Hockley, Kimberley; Thomson, Andrew Journal: Biometrical journal Issue: Volume 58:Issue 1(2016:Jan.) Page Start: 8 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Benefit–risk assessment in a post‐market setting: a case study integrating real‐life experience into benefit–risk methodology†. (5th July 2014) Authors: Hallgreen, Christine E.; van den Ham, Hendrika A.; Mt‐Isa, Shahrul; Ashworth, Simon; Hermann, Richard; Hobbiger, Steve; Luciani, Davide; Micaleff, Alain; Thomson, Andrew; Wang, Nan; van Staa, Tjeerd P.; Downey, Gerald; Hirsch, Ian; Hockley, Kimberley; Juhaeri, Juhaeri; Metcalf, Marilyn; Mwangi, J... Journal: Pharmacoepidemiology and drug safety Issue: Volume 23:Number 9(2014:Sep.) Page Start: 974 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. High correlation of VAS pain scores after 2 and 6 weeks of treatment with VAS pain scores at 12 weeks in randomised controlled trials in rheumatoid arthritis and osteoarthritis: meta-analysis and implications. Issue 1 (December 2016) Authors: Karabis, Andreas; Nikolakopoulos, Stavros; Pandhi, Shaloo; Papadimitropoulou, Katerina; Nixon, Richard; Chaves, Ricardo; Moore, R. Journal: Arthritis research & therapy Issue: Volume 18:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27. (January 2015) Authors: Nixon, Richard; Capkun-Niggli, Gorana; Bergvall, Niklas; Dias, Sofia Journal: Current medical research and opinion Issue: Volume 31:Number 1(2015:Jan.) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Re: Hutchinson M, Fox RJ, Havrdova E, et al. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease modifying therapies for the treatment of relapsing–remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin 2014;30:613-27. (January 2015) Authors: Nixon, Richard; Capkun-Niggli, Gorana; Bergvall, Niklas; Dias, Sofia Journal: Current medical research and opinion Issue: Volume 31:Number 1(2015:Jan.) Page Start: 51 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Review and comparison of methodologies for indirect comparison of clinical trial results: an illustration with ranibizumab and aflibercept. (1st November 2016) Authors: Regnier, Stephane A.; Alsop, Jonathan; Wright, Jonathan; Nixon, Richard; Staines, Harry; Fajnkuchen, Franck Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 16:Number 6(2016) Page Start: 793 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗